Xpert MTB/RIF Cycle Threshold as a Marker of Tuberculosis (TB) Disease Severity: Implications for TB Treatment Stratification
The TB phenotype classification derived here successfully identified three-quarters of RIFASHORT trial participants for whom a 4-month 1200-mg rifampicin regimen was noninferior to the 6-month standard of care. A definitive phase III randomized trial of disease-stratified rifampicin-based TB treatment is justified.
Authors
- Katherine A. Gould (ORCID: https://orcid.org/0000-0002-2528-9512)
- Daniel J. Grint (ORCID: https://orcid.org/0000-0001-8001-6544)
- Ken Laing (ORCID: https://orcid.org/0000-0003-1883-3433)
- Katherine Fielding (ORCID: https://orcid.org/0000-0002-6524-3754)
- Amina Jindani (ORCID: https://orcid.org/0000-0002-7110-5286)
- Thomas S. Harrison (ORCID: https://orcid.org/0000-0003-3619-4348)
- C S G Cousins (ORCID: https://orcid.org/0009-0008-3855-8217)
- Tulika Munshi
- Adam A. Witney (ORCID: https://orcid.org/0000-0003-4561-7170)
- Jack Adams (ORCID: https://orcid.org/0009-0009-0586-7758)
- Philip D. Butcher (ORCID: https://orcid.org/0000-0003-1223-9097)
- Jasvir Dhillon
- Sean Wasserman (ORCID: https://orcid.org/0000-0002-3508-6719)
Institutions
- University of Cape Town (ZA)
- St George's, University of London (GB)
- London School of Hygiene & Tropical Medicine (GB)
- Wellcome Centre for Infectious Diseases Research in Africa (ZA)
- Institute of Infection and Immunity (CA)
- City St George's, University of London (GB)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2025-09-23
- DOI
- https://doi.org/10.1093/cid/ciaf527
- Primary Topic
- Tuberculosis Research and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00